General
Preferred name
Vidofludimus
Synonyms
SC12267 ()
4SC-101 ()
IMU-838 ()
SC12267, 4SC-101 ()
SC-12267 ()
NSC-717824 ()
P&D ID
PD012716
CAS
717824-30-1
Tags
available
drug candidate
Drug indication
Coronavirus Disease 2019 (COVID-19)
Ulcerative colitis
Inflammatory bowel disease
Rheumatoid arthritis
Drug Status
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR[1][2][3].
PRICE
97
DESCRIPTION
Vidofludimus (4SC-101) is a small molecule dihydroorotate dehydrogenase (DHOD) inhibitor that was developed for immunosuppressive potential . It has an improved toxicity profile in comparison to the clinically used disease modifying anti-rheumatic drug (DMARD) .
Since its initial development, vidofludimus has been superceded by IMU-838 which is an orally active polymorph of vidofludimus calcium (PubChem CID: 56944639) .
SARS-CoV-2 and COVID-19: The target of vidofludimus, DHODH, plays a role in the metabolism of activated T cells and B cells to regulate the inflammatory response. It has been advanced to clinical trial in patients with severe COVID-19, to as attempt to block the release of pro-inflammatory cytokines and temper hyperinflammation in these patients. (GtoPdb)
Since its initial development, vidofludimus has been superceded by IMU-838 which is an orally active polymorph of vidofludimus calcium (PubChem CID: 56944639) .
SARS-CoV-2 and COVID-19: The target of vidofludimus, DHODH, plays a role in the metabolism of activated T cells and B cells to regulate the inflammatory response. It has been advanced to clinical trial in patients with severe COVID-19, to as attempt to block the release of pro-inflammatory cytokines and temper hyperinflammation in these patients. (GtoPdb)
DESCRIPTION
Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
14
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
26
Molecular Weight
355.12
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
4.0
TPSA
75.63
Fraction CSP3
0.2
Chiral centers
0.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Human DHODH
Interleukin
IL17A
DHODH inhibitor
FXR
Interleukin Related
COVID-19,Dehydrogenase
Member status
member
MOA
Anti-IL-17
Dihydroorotate Dehydrogenase (DHODH) Inhibitors
dihydroorotate dehydrogenase inhibitor
Pathway
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Immunology/Inflammation
Metabolism
Metabolic Enzyme/Protease
Therapeutic Class
Antiviral Agents
Source data
